

## Lynparza® (olaparib) – Voluntary indication withdrawal

- On August 26, 2022, the <u>FDA approved</u> a voluntary indication withdrawal for AstraZeneca's <u>Lynparza (olaparib)</u>, for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
- This decision does not affect the other approved indications for Lynparza, which include:
  - First-line maintenance treatment of BRCA-mutated advanced ovarian cancer
  - First-line maintenance treatment of homologous recombination deficiency (HRD)-positive advanced ovarian cancer in combination with bevacizumab
  - Maintenance treatment of recurrent ovarian cancer
  - Adjuvant treatment of germline BRCA-mutated human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer
  - Germline BRCA-mutated HER2-negative metastatic breast cancer
  - First-Line maintenance treatment of germline BRCA-mutated metastatic pancreatic adenocarcinoma
  - Homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.